Virus-specific antibodies to Epstein-Barr virus, varicella-zoster virus and rubella virus in renal transplant patients with cytomegalovirus infections

Costimulation Blockade in Vascularized Composite Allotransplantation

Vascular composite allotransplantation (VCA) is a field under research and has emerged as an alternative option for the repair of severe disfiguring defects that result from infections or traumatic amputation in a selected group of patients. VCA is performed in centers with appropriate expertise, experience and adequate resources to effectively manage the complexity and complications of this treatment. Lifelong immunosuppressive therapy, immunosuppression associated complications, and the effects of the host immune response in the graft are major concerns in VCA. VCA is considered a quality of life transplant and the risk-benefit ratio is dissimilar to life saving transplants. Belatacept seems a promising drug that prolongs patient and graft survival in kidney transplantation and it could also be an alternative approach to VCA immunosuppression. In this review, we are summarizing current literature about the role of costimulation blockade, with a focus on belatacept in VCA.

Seroepidemiology of herpes virus infections among dental personnel

OBJECTIVES

To examine the possible occupational hazard of infection with human herpes viruses among dental personnel.

METHODS

Sera from 81 preclinical dental students, 53 clinical dental students and 103 qualified dental surgeons were tested for antibodies to herpes simplex virus type 1 (HSV-1), cytomegalovirus (CMV), Epstein-Barr virus (EBV) and human herpes virus type 6 (HHV-6). The same number of control subjects, matched individually for age (+/- 1 year), sex and social class, was also examined. Antibodies were detected by ELISA for HSV-1, latex agglutination for CMV, indirect immunofluorescence with P3HR1 cells for EBV and indirect immunofluorescence with infected JJhan cells for HHV-6. Each participant also completed a questionnaire to permit correlation of demographic data and risk factors with serological results.

RESULTS

No significant difference in seroprevalence was detected between any of the dental groups and their respective controls. There was a significantly higher prevalence of antibodies to EBV among clinical students (P = 0.02) and qualified dentists (P = 0.0003) than among preclinical students. These significant increases were not mirrored in the three corresponding control groups.

CONCLUSION

The results suggest a possible occupational risk of infection with EBV in dentists. There was no evidence for a significant risk of occupational infection with HSV-1, CMV or HHV-6.

Evaluation of a new reagent for anti-cytomegalovirus and anti-Epstein-Barr virus immunoglobulin G

The Enzygnost alpha method was tested against the complement fixation test and anti-VCA immunofluorescence to determine the respective titers of anti-cytomegalovirus and anti-Epstein-Barr virus immunoglobulin G antibodies. For cytomegalovirus, the Enzygnost results showed 97.99% agreement with the readings obtained by the alternative method, with 100% sensitivity and 93.7% specificity. For Epstein-Barr virus, Enzygnost showed 97.71% agreement, 100% sensitivity, and 91.11% specificity.